Results 151 to 160 of about 47,525 (299)

Metabolism of Desipramine in Japanese Psychiatric Patients: The Impact of CYP2D6 Genotype on the Hydroxylation of Desipramine [PDF]

, 2000
Kazutaka Shimoda, Sachiyo Morita, Genta Hirokane, Aya Yokono, Toshiyuki Someya, Saburo Takahashi   +5 more
openalex   +1 more source

External validation of a therapeutic window for risperidone in children with autism spectrum disorder

British Journal of Clinical Pharmacology, Volume 91, Issue 10, Page 3009-3015, October 2025.
Abstract Although risperidone is an effective pharmacological intervention for managing disruptive behaviour in children with autism spectrum disorder, it may induce metabolic side effects. This study aimed to externally validate the population pharmacokinetic (popPK) model and the therapeutic window of 3.5–7 ng/mL of risperidone and 9‐OH‐risperidone ...
Rebecca A. Hermans, Kathalijne Bruens, Karin M. Egberts, Birgit C. P. Koch, Bram Dierckx, Manon H. J. Hillegers, Marcel Romanos, Regina Taurines, Stefanie Fekete, Khatia Eisenecker, Hans‐Willi Clement, Christian Fleischhaker, Brenda C. M. de Winter   +12 more
wiley   +1 more source

UPLC‐ESI‐QTOF‐MS/MS Profiling, Antioxidant, and Cytotoxicity Potentials of Marrubium vulgare L. Extracts: Experimental Analysis and Computational Validation

Chemistry &Biodiversity, Volume 22, Issue 10, October 2025.
ABSTRACT Plant extracts are emerging as valuable options for food additives and therapeutic treatments. This study evaluated the phytochemical profile, antioxidant activity, and cytotoxicity of aerial parts of Marrubium vulgare L. crude extract (MVCE) and its subfractions.
Ines El Mannoubi, Nuha M. Alghamdi, Seham H. Bashir, Suada Alsaied Mohamed, Hedia Chaabane, Ashraf N. Abdalla, Majdi Abid, Adel Kadri, Mozaniel Santana de Oliveira   +8 more
wiley   +1 more source

FROM THE EDITOR

Фармакокинетика и Фармакодинамика, 2014
В настоящем номере представлен ряд актуальных обзоров, посвящённых изучению новых лекарственных средств и межлекарственному взаимодействию. Прежде всего, продолжается серия обзоров, связанных с исследованием функционирования и полиморфизма известных ...

doaj  

Flavonoid Profile, Biological Potentials, and In Silico Approaches of Methanol Extracts on AChE: Amaranthus retroflexus L.

Chemistry &Biodiversity, Volume 22, Issue 10, October 2025.
ABSTRACT This study investigated the flavonoid compounds and their biological activities in methanol extracts obtained from root, stem, leaf, and flower parts of Amaranthus retroflexus L. Flavonoids in the extracts were characterized for the first time by liquid chromatography–highresolution mass spectrometry (LC–HRMS), and a total of eight flavonoid ...
Bedrettin Selvi, Güler Durmuş, Mustafa Ceylan, Şuheda Yıldırım, Ümit M. Koçyiğit, Ümit Yırtıcı, Volkan Eyüpoğlu   +6 more
wiley   +1 more source

Review of existing methodologies to assess the activity of CYP2D6 using exogenous and endogenous markers

Фармакокинетика и Фармакодинамика, 2014
Peculiarities of functioning and polymorphism of cytochrome P450 isoenzyme CYP2D6. Existing methods for determining its activity using endogenous markers.
A. D. Abdrashitov, G. N. Gildeeva, G. V. Ramenskaya, V. V. Smirnov   +3 more
doaj  

Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity

Human Genomics
Background Individual assessment of CYP enzyme activities can be challenging. Recently, the potato alkaloid solanidine was suggested as a biomarker for CYP2D6 activity.
Johanna I. Kiiski, Mikko Neuvonen, Mika Kurkela, Päivi Hirvensalo, Kreetta Hämäläinen, E. Katriina Tarkiainen, Johanna Sistonen, Mari Korhonen, Sofia Khan, Arto Orpana, Anne M. Filppula, Marko Lehtonen, Mikko Niemi   +12 more
doaj   +1 more source

New opportunities in cancer risk evaluation using PCR-based DNA analysis for CYP2D6.

, 1993
Jeffrey R. Idle, Ann K. Daly
openalex   +1 more source

CYP2D6 Genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting [PDF]

, 2000
Suzin McElroy, Jodi Richmond, Maruja Lira, David L. Friedman, B. Michael Silber, Patrice M. Milos, Christoph Sachse, Jürgen Brockmöller, Ivar Roots   +8 more
openalex   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 778-789, October 2025.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source